• +1-646-491-9876
    • +91-20-67278686

    Search

    Hepatitis B-Pipeline Review H1 2017

    Hepatitis B-Pipeline Review H1 2017

    • Report Code ID: RW0001834332
    • Category Pharmaceuticals
    • No. of Pages 353
    • Publication Month May-17
    • Publisher Name Global Markets Direct
    Hepatitis B - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Hepatitis B - Pipeline Review, H1 2017, provides an overview of the Hepatitis B (Infectious Disease) pipeline landscape.

    Hepatitis B is a potentially life-threatening liver infection caused by the hepatitis B virus. Hepatitis B virus can cause an acute illness with symptoms that last several weeks, including yellowing of the skin and eyes (jaundice) , dark urine, extreme fatigue, nausea, vomiting and abdominal pain. Risk factors include age, severe kidney disease, hemophilia, share needles during drug use and born to a hepatitis-b infected mother. Treatment includes antiviral drugs.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Hepatitis B - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Hepatitis B (Infectious Disease) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Hepatitis B (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hepatitis B and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 2, 8, 27, 26, 4, 56, 35 and 4 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 3, 9 and 5 molecules, respectively.

    Hepatitis B (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatitis B (Infectious Disease) .
    - The pipeline guide reviews pipeline therapeutics for Hepatitis B (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Hepatitis B (Infectious Disease) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Hepatitis B (Infectious Disease) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Hepatitis B (Infectious Disease)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Hepatitis B (Infectious Disease) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Hepatitis B (Infectious Disease) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents 2
    Introduction 6
    Hepatitis B - Overview 7
    Hepatitis B - Therapeutics Development 8
    Hepatitis B - Therapeutics Assessment 27
    Hepatitis B - Companies Involved in Therapeutics Development 37
    Hepatitis B - Drug Profiles 79
    Hepatitis B - Dormant Projects 317
    Hepatitis B - Discontinued Products 324
    Hepatitis B - Product Development Milestones 325
    Appendix 334

    List of Tables

    Number of Products under Development for Hepatitis B, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..3) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..4) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..5) , H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..3) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..4) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..5) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..6) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..7) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..8) , H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Hepatitis B - Pipeline by Abivax SA, H1 2017
    Hepatitis B - Pipeline by AiCuris GmbH & Co KG, H1 2017
    Hepatitis B - Pipeline by AIMM Therapeutics BV, H1 2017
    Hepatitis B - Pipeline by Akshaya Bio Inc, H1 2017
    Hepatitis B - Pipeline by Alnylam Pharmaceuticals Inc, H1 2017
    Hepatitis B - Pipeline by Altimmune Inc, H1 2017
    Hepatitis B - Pipeline by Altravax Inc, H1 2017
    Hepatitis B - Pipeline by Amarna Therapeutics BV, H1 2017
    Hepatitis B - Pipeline by Arbutus Biopharma Corp, H1 2017
    Hepatitis B - Pipeline by Arcturus Therapeutics Inc, H1 2017
    Hepatitis B - Pipeline by Arrowhead Pharmaceuticals Inc, H1 2017
    Hepatitis B - Pipeline by Assembly Biosciences Inc, H1 2017
    Hepatitis B - Pipeline by Beijing Kawin Technology Share-Holding Co Ltd, H1 2017
    Hepatitis B - Pipeline by Beijing Minhai Biotechnology Co Ltd, H1 2017
    Hepatitis B - Pipeline by Benitec Biopharma Ltd, H1 2017
    Hepatitis B - Pipeline by Biological E Ltd, H1 2017
    Hepatitis B - Pipeline by BioStar Pharmaceuticals Inc, H1 2017
    Hepatitis B - Pipeline by Bolder Biotechnology Inc, H1 2017
    Hepatitis B - Pipeline by BrightGene Bio-Medical Technology Co Ltd, H1 2017
    Hepatitis B - Pipeline by Bukwang Pharm Co Ltd, H1 2017
    Hepatitis B - Pipeline by CaroGen Corp, H1 2017
    Hepatitis B - Pipeline by Celltrion Inc, H1 2017
    Hepatitis B - Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2017
    Hepatitis B - Pipeline by Chromis Therapeutics Inc, H1 2017
    Hepatitis B - Pipeline by Cocrystal Pharma Inc, H1 2017
    Hepatitis B - Pipeline by ContraVir Pharmaceuticals Inc, H1 2017
    Hepatitis B - Pipeline by CyTuVax BV, H1 2017
    Hepatitis B - Pipeline by Dicerna Pharmaceuticals Inc, H1 2017
    Hepatitis B - Pipeline by Dong-A Socio Holdings Co Ltd, H1 2017
    Hepatitis B - Pipeline by Dynavax Technologies Corp, H1 2017
    Hepatitis B - Pipeline by Ensemble Therapeutics Corp, H1 2017
    Hepatitis B - Pipeline by Enyo Pharma SA, H1 2017
    Hepatitis B - Pipeline by eTheRNA Immunotherapies NV, H1 2017
    Hepatitis B - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
    Hepatitis B - Pipeline by GeneCure LLC, H1 2017
    Hepatitis B - Pipeline by GeoVax Labs Inc, H1 2017
    Hepatitis B - Pipeline by Gilead Sciences Inc, H1 2017
    Hepatitis B - Pipeline by GlaxoSmithKline Plc, H1 2017
    Hepatitis B - Pipeline by Green Cross Corp, H1 2017
    Hepatitis B - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017
    Hepatitis B - Pipeline by Humabs BioMed SA, H1 2017
    Hepatitis B - Pipeline by Huons Co Ltd, H1 2017
    Hepatitis B - Pipeline by Ildong Pharmaceutical Co Ltd, H1 2017
    Hepatitis B - Pipeline by Immunotope Inc, H1 2017
    Hepatitis B - Pipeline by Indian Immunologicals Ltd, H1 2017
    Hepatitis B - Pipeline by Intellia Therapeutics Inc, H1 2017
    Hepatitis B - Pipeline by Ionis Pharmaceuticals Inc, H1 2017
    Hepatitis B - Pipeline by ISA Pharmaceuticals BV, H1 2017
    Hepatitis B - Pipeline by Jiangsu Hansoh Pharmaceutical Group Co Ltd, H1 2017
    Hepatitis B - Pipeline by Johnson & Johnson, H1 2017
    Hepatitis B - Pipeline by Kineta Inc, H1 2017
    Hepatitis B - Pipeline by Leukocare AG, H1 2017
    Hepatitis B - Pipeline by LG Chem, Ltd., H1 2017
    Hepatitis B - Pipeline by Ligand Pharmaceuticals Inc, H1 2017
    Hepatitis B - Pipeline by Medivir AB, H1 2017
    Hepatitis B - Pipeline by Mucosis BV, H1 2017
    Hepatitis B - Pipeline by MultiCell Technologies Inc, H1 2017
    Hepatitis B - Pipeline by Oncolys BioPharma Inc, H1 2017
    Hepatitis B - Pipeline by Panacea Biotec Ltd, H1 2017
    Hepatitis B - Pipeline by Pfenex Inc, H1 2017
    Hepatitis B - Pipeline by PharmaEssentia Corp, H1 2017
    Hepatitis B - Pipeline by Profarma, H1 2017
    Hepatitis B - Pipeline by Profectus BioSciences Inc, H1 2017
    Hepatitis B - Pipeline by Replicor Inc, H1 2017
    Hepatitis B - Pipeline by Rodos BioTarget GmbH, H1 2017
    Hepatitis B - Pipeline by Samjin Pharmaceutical Co Ltd, H1 2017
    Hepatitis B - Pipeline by Sanofi, H1 2017
    Hepatitis B - Pipeline by Sanofi Pasteur SA, H1 2017
    Hepatitis B - Pipeline by Scynexis Inc, H1 2017
    Hepatitis B - Pipeline by Shantha Biotechnics Ltd, H1 2017
    Hepatitis B - Pipeline by Sinovac Biotech Ltd, H1 2017
    Hepatitis B - Pipeline by Spring Bank Pharmaceuticals Inc, H1 2017
    Hepatitis B - Pipeline by TCM Biotech International Corp, H1 2017
    Hepatitis B - Pipeline by Theravectys SA, H1 2017
    Hepatitis B - Pipeline by THEVAX Genetics Vaccine USA Inc, H1 2017
    Hepatitis B - Pipeline by Tomegavax Inc, H1 2017
    Hepatitis B - Pipeline by Transgene SA, H1 2017
    Hepatitis B - Pipeline by Vaxine Pty Ltd, H1 2017
    Hepatitis B - Pipeline by VBI Vaccines Inc, H1 2017
    Hepatitis B - Pipeline by Vical Inc, H1 2017
    Hepatitis B - Pipeline by ViroStatics srl, H1 2017
    patitis B - Pipeline by VLP Biotech Inc, H1 2017
    Hepatitis B - Pipeline by Zydus Cadila Healthcare Ltd, H1 2017
    Hepatitis B - Dormant Projects, H1 2017
    Hepatitis B - Dormant Projects, H1 2017 (Contd..1) , H1 2017
    Hepatitis B - Dormant Projects, H1 2017 (Contd..2) , H1 2017
    Hepatitis B - Dormant Projects, H1 2017 (Contd..3) , H1 2017
    Hepatitis B - Dormant Projects, H1 2017 (Contd..4) , H1 2017
    Hepatitis B - Dormant Projects, H1 2017 (Contd..5) , H1 2017
    Hepatitis B - Dormant Projects, H1 2017 (Contd..6) , H1 2017
    Hepatitis B - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Hepatitis B, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Top 10 Routes of Administration, H1 2017
    Number of Products by Stage and Top 10 Routes of Administration, H1 2017
    Number of Products by Top 10 Molecule Types, H1 2017
    Number of Products by Stage and Top 10 Molecule Types, H1 2017
    Abivax SA
    AiCuris GmbH & Co KG
    AIMM Therapeutics BV
    Akshaya Bio Inc
    Alnylam Pharmaceuticals Inc
    Altimmune Inc
    Altravax Inc
    Amarna Therapeutics BV
    Arbutus Biopharma Corp
    Arcturus Therapeutics Inc
    Arrowhead Pharmaceuticals Inc
    Assembly Biosciences Inc
    Beijing Kawin Technology Share-Holding Co Ltd
    Beijing Minhai Biotechnology Co Ltd
    Benitec Biopharma Ltd
    Biological E Ltd
    BioStar Pharmaceuticals Inc
    Bolder Biotechnology Inc
    BrightGene Bio-Medical Technology Co Ltd
    Bukwang Pharm Co Ltd
    CaroGen Corp
    Celltrion Inc
    Chong Kun Dang Pharmaceutical Corp
    Chromis Therapeutics Inc
    Cocrystal Pharma Inc
    ContraVir Pharmaceuticals Inc
    CyTuVax BV
    Dicerna Pharmaceuticals Inc
    Dong-A Socio Holdings Co Ltd
    Dynavax Technologies Corp
    Ensemble Therapeutics Corp
    Enyo Pharma SA
    eTheRNA Immunotherapies NV
    F. Hoffmann-La Roche Ltd
    GeneCure LLC
    GeoVax Labs Inc
    Gilead Sciences Inc
    GlaxoSmithKline Plc
    Green Cross Corp
    Hanmi Pharmaceuticals Co Ltd
    Humabs BioMed SA
    Huons Co Ltd
    Ildong Pharmaceutical Co Ltd
    Immunotope Inc
    Indian Immunologicals Ltd
    Intellia Therapeutics Inc
    Ionis Pharmaceuticals Inc
    ISA Pharmaceuticals BV
    Jiangsu Hansoh Pharmaceutical Group Co Ltd
    Johnson & Johnson
    Kineta Inc
    Leukocare AG
    LG Chem, Ltd.
    Ligand Pharmaceuticals Inc
    Medivir AB
    Mucosis BV
    MultiCell Technologies Inc
    Oncolys BioPharma Inc
    Panacea Biotec Ltd
    Pfenex Inc
    PharmaEssentia Corp
    Profarma
    Profectus BioSciences Inc
    Replicor Inc
    Rodos BioTarget GmbH
    Samjin Pharmaceutical Co Ltd
    Sanofi
    Sanofi Pasteur SA
    Scynexis Inc
    Shantha Biotechnics Ltd
    Sinovac Biotech Ltd
    Spring Bank Pharmaceuticals Inc
    TCM Biotech International Corp
    Theravectys SA
    THEVAX Genetics Vaccine USA Inc
    Tomegavax Inc
    Transgene SA
    Vaxine Pty Ltd
    VBI Vaccines Inc
    Vical Inc
    ViroStatics srl
    VLP Biotech Inc
    Zydus Cadila Healthcare Ltd

    Request for Sample

    Report Url http://www.reportsweb.com//hepatitis-b-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//hepatitis-b-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//hepatitis-b-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments